There are multiple routes that researchers can and have continued to take in the quest of finding therapies for various illnesses, conditions or disorders. Investigation of oncolytic viruses for the treatment of cancer is one of those approaches
Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028 Report Overview:
- Global Oncolytic Virus Immunotherapy Therapy Market Overview
- Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1 Billion By 2028
- Insight On More Than 180 Oncolytic Virus Immunotherapies In Clinical Trials
- Patent Information On More Than 60 Therapies in Clinical Trials
- IMLYGIC, Oncorine, Delytact: Availability, Dosage & Price Analysis
- Oncolytic Virus Immunotherapy Clinical Pipeline By Country, Phase, Indication, Organization, Patient Segment
- Oncolytic Virus Immunotherapy Application By 10 Cancer
- Recent Strategic Partnerships, Collaborations, Mergers & Acquisitions
Download Report:
There are multiple routes that researchers can and have continued to take in the quest of finding therapies for various illnesses, conditions or disorders. Investigation of oncolytic viruses for the treatment of cancer is one of those approaches. Oncolytic viruses are one of the newest areas of cancer therapies, and their special qualities have been harnessed for use in the treatment of cancer. Despite a sluggish beginning, oncolytic virus development has picked up significantly in recent years, and the encouraging results from ongoing clinical trials are anticipated to drive additional growth in the clinical pipeline and the market in the years to come.
Oncolytic viruses differ from typical viruses in that they can specifically target cancer cells. They are often driven to cancer cells because they need the aberrated signaling pathways that are frequently seen in cancer cells for proliferation. A number of candidates have entered the pipeline as a result of the targetability of oncolytic viruses for cancer cells being used in clinical practice, mostly for solid tumors. There are now more than 80 clinical trials evaluating several oncolytic virus candidates, the majority of which are in the early stages of trials. One of the earliest oncolytic viral candidates to enter clinical trials was Talimogene Laherparepvec, or T-VEC, which is still the only oncolytic virus to have received FDA and EMA authorization for commercial sale. The combination of T-VEC with Keytruda (Pembrolizumab) remains one of the most popular combinations to be evaluated in clinical trials for a number of cancer indications.
Like any other immunotherapeutic approach, the combination of oncolytic viruses have been tested with immune checkpoint inhibitors as well. Pexastimogene devacirepvec, also known as JX-594 or Pexa-Vec is in a phase 1/2 clinical trial in combination with Durvalumab and Tremelimumab, approved monoclonal antibodies targeting the PD-1 and CTLA-4. PD-1 and CTLA-4 inhibition are the two most popular immunotherapy approaches which have proved their efficacy in many patients over the years. Combining them with oncolytic viruses enhances their anti-cancer abilities and prevents T-cell anergy in the tumor microenvironment, a commonly observed phenomenon.
As oncolytic viruses have grown in popularity around the world, a number of partnerships and collaborations have been reported that are advantageous for accelerating the development of oncolytic viruses and enabling a quicker entry of highly effective candidates in clinical trials. A Cooperative Research and Development Agreement (CRADA) was recently announced by Turnstone Biologics with the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH). The parties aim to evaluating how Turnstone’s exclusive oncolytic viruses affect the immune response to tumor neoantigens in clinical patient samples as per the terms of the CRADA. This came only a month after Turnstone and OxSonics Therapeutics collaborated to present a poster on improving delivery and efficiency of an unarmed enhanced oncolytic vaccinia virus (VV) in a murine bladder cancer model. The poster focused on transforming cancer treatment using the latter’s ultrasound-based drug delivery platform, SonoTran.
An additional strategic partnership between Virogin Biotech and The University of Texas MD Anderson Cancer Center todaywas established last year in an effort to expedite the creation of innovative oncolytic virus therapies for patients suffering from advanced cancer. Through the collaboration, the novel portfolio of potential oncolytic viruses from Virogin and MD Anderson’s competence and facilities in clinical trials are combined. The five-year partnership will aid in the clinical development of Virogin’s treatments through numerous clinical trials in different cancer types to assess their efficacy and safety as well as to find prognostic biomarkers of response.
Providing one of most superior options to develop beneficial combinations with immune checkpoint inhibition and other immunotherapies, oncolytic viruses have the potential to be highly targeted treatments that increase anti-tumor immune responses in cancer patients. The domain has long gone beyond its nascent stage and the arrival of several potential candidates in the clinical pipeline demonstrates a promising future for this treatment modality. At present, only three candidates are commercially available in different parts of the world but the possibilities of enhancing the anti-tumor effects of existing immunotherapies with oncolytic viruses is immense and will be one of the key driving factors in the coming years.
Contact:
Neeraj Chawla
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com